European Heart Journal Advance Access published online on October 13, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl318
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Université Paris 7, Denis Diderot, Laboratoire de pathologie Infectieuse, Paris, France; AP-HP Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, 46 rue Henri Huchard, 75877 Paris, Cedex 18, France; Inserm, U738 Paris, France
* To whom correspondence should be addressed. Aims To analyse the characteristics of infective endocarditis (IE) in patients with diabetes mellitus (DM), and to evaluate the prognostic significance of DM according to insulin use. Methods and results A total of 559 patients with definite IE including 75 patients (13%) with DM (insulin use n = 22; oral antidiabetic n = 53) were evaluated. Comparison of insulin-DM, oral-DM, and non-DM patients showed an older age (66 ± 13, 66 ± 10, 58 ± 17, respectively; P = 0.004) in DM patients, and more frequent IE on prosthetic valves (32, 11, and 15%, respectively; P = 0.068) in insulin-DM patients. Oral streptococci (0, 8, and 18%, respectively; P = 0.016) were less frequently the causative organism than staphylococci (64, 26, and 29%, respectively; P = 0.002) in insulin-DM patients. Vegetations, dehiscence, abscess, and regurgitation rates did not differ among the three groups, nor did cardiac surgery rates (32, 47, and 48%, respectively; P = 0.334), but in-hospital mortality was higher in insulin-DM patients (50, 19, and 15%; P < 0.001). In multivariable analysis, independently of other determinants of death (age, IE location, Staphylococcus aureus, history of heart failure, immunosuppression, creatinine serum), insulin-DM was a predictor of death (OR, 4.69; 95% CI, 1.77-12.44), whereas oral-DM was not. Conclusion IE prognosis in insulin-DM patients is poor due to the coexistence of host and pathogen factors. Insulin-DM patients with IE may require specific management.
Received March 6, 2006
Revised September 14, 2006
Accepted September 28, 2006
Clinical research
Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality
Xavier Duval 1 *, François Alla 2, Thanh Doco-Lecompte 2, Vincent Le Moing 3, François Delahaye 4, Jean-Luc Mainardi 5, Patrick Plesiat 6, Marie Célard 4, Bruno Hoen 6, and Catherine Leport 7, for the Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI)
2 Centre hospitalier Universitaire, Nancy, France
3 Centre hospitalier Universitaire, Guy de Chauliac, Montpellier, France
4 Centre hospitalier Universitaire, Lyon, France
5 Université Paris-Descartes, Faculté de Médecine, Paris, France; AP-HP Hôpital Européen Georges Pompidou, Paris, France
6 Centre hospitalier Universitaire, Besançon, France
7 Université Paris 7, Denis Diderot, Laboratoire de pathologie Infectieuse, Paris, France; AP-HP Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, 46 rue Henri Huchard, 75877 Paris, Cedex 18, France
Xavier Duval, E-mail: xavier.duval{at}bch.aphp.fr
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. M. Jolic{oelig}ur, W. W. O'Neill, A. Hellkamp, C. W. Hamm, D. R. Holmes Jr., H. R. Al-Khalidi, M. R. Patel, F. J. Van de Werf, K. Pieper, P. W. Armstrong, et al. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention Eur. Heart J., November 1, 2009; 30(21): 2575 - 2583. [Abstract] [Full Text] [PDF] |
||||
![]() |
Endorsed by the European Society of Clinical Micro, Authors/Task Force Members, G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, I. Vilacosta, P. Moreillon, M. de Jesus Antunes, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC) Eur. Heart J., October 1, 2009; 30(19): 2369 - 2413. [Full Text] [PDF] |
||||
![]() |
A. M. Sheikh, A. M. Elhenawy, M. Maganti, S. Armstrong, T. E. David, and C. M. Feindel Outcomes of double valve surgery for active infective endocarditis J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 69 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bannay, B. Hoen, X. Duval, J.-F. Obadia, C. Selton-Suty, V. Le Moing, P. Tattevin, B. Iung, F. Delahaye, F. Alla, et al. The impact of valve surgery on short- and long-term mortality in left-sided infective endocarditis: do differences in methodological approaches explain previous conflicting results? Eur. Heart J., February 9, 2009; (2009) ehp008v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Kristensen, H. Baumgartner, H. Drexler, E. Eeckhout, G. Filippatos, A. K. Gitt, C. Linde, L. A. Pierard, D. Poldermans, H. Schunkert, et al. Highlights of the 2007 Scientific Sessions of the European Society of Cardiology: Vienna, Austria, September 1 5, 2007 J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2421 - 2430. [Full Text] [PDF] |
||||
![]() |
A. Wang Diabetes mellitus and insulin therapy in infective endocarditis Eur. Heart J., January 1, 2007; 28(1): 3 - 4. [Full Text] [PDF] |
||||


